Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
224807
千円（2024年6月期の承継事業売上高）Wording
Conditional
How definitive the wording is.This transaction
Name of transactionCounterparty (target company)エヌピーエス株式会社
Disclosing companyPrecision System Science Co.,Ltd.
TimelineThe spacing between the points is proportional to the actual number of days.White points represent dates designated as scheduled dates in the document.
Target company
遺伝子検査用・バイオ研究用の試薬及び機器の開発・設計・製造
Location 秋田県大館市Share capital 800百万円（2024年12月31日時点）Date of incorporation 2008年２月１日
Net Sales610,785千円（2024年６月期）
Operating profit営業損失（△）△182,976千円（2024年６月期）
Net income for the current fiscal year当期純損失（△）△194,595千円（2024年６月期）
Net assets378,249千円（2024年６月期）
Consideration and expenses
Acquisition priceNo allocation of shares or other monetary consideration
Type of ConsiderationNo consideration (no allocation of shares or other monetary consideration)
Impact on Business Performance
The impact on the Company's consolidated results will be minor.
Procedures and assumptions
Conditions Precedent to Execution株主総会による吸収分割契約の承認を受けることなく行います。
Management structure after acquisition本吸収分割による、当社の名称、所在地、代表者の役職・氏名、事業内容、資本金および決算期に変更はありません。
| Item | Details |
|---|---|
| Transaction name | Name of transaction |
| Counterparty name | エヌピーエス株式会社 |
| Name of the Subject Company | エヌピーエス株式会社 |
| Business Description of the Subject Company | 遺伝子検査用・バイオ研究用の試薬及び機器の開発・設計・製造 |
| Location of the Subject Company | 秋田県大館市 |
| Capital Stock of the Subject Company | 800百万円（2024年12月31日時点） |
| Date of Establishment of the Subject Company | 2008年２月１日 |
| Net Sales of the Subject Company | 610,785千円（2024年６月期） |
| Operating Profit of the Subject Company | 営業損失（△）△182,976千円（2024年６月期） |
| Net Income of the Subject Company | 当期純損失（△）△194,595千円（2024年６月期） |
| Net Assets of the Subject Company | 378,249千円（2024年６月期） |
| Acquisition price | No allocation of shares or other monetary consideration |
| Type of Consideration | No consideration (no allocation of shares or other monetary consideration) |
| Voting rights ownership percentage | Before 100％（2024年12月31日時点） (after not disclosed) |
| Impact on Business Performance | The impact on the Company's consolidated results will be minor. |
| Date of board resolution | 15 May 2025 |
| Contract Date | 15 May 2025 |
| Execution Date / Effective Date | 2025年７月1日（予定） |
| Conditions Precedent to Execution | 株主総会による吸収分割契約の承認を受けることなく行います。 |
| Management structure after acquisition | 本吸収分割による、当社の名称、所在地、代表者の役職・氏名、事業内容、資本金および決算期に変更はありません。 |
Items this document does not state (12)
Expenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Valuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.試薬製造及び消耗材製造事業を当社が円滑に承継し、当事業の効率を高めるとともに、迅速な経営判断を行うため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.